Brise Pharma Announces First Patient Dosed with BR01T in Phase I Study in Patients with Chronic Low Back Pain
The trial focuses on the safety and tolerability study of BR01T, a groundbreaking monoclonal antibody designed to target Tropomyosin Receptor Kinase (TrkA) for addressing Chronic Low Back Pain (CLBP).